Insulin and glucagon secretion: nondiabetic and diabetic subjects.

Slides:

Advertisements

Similar presentations

Role of Amylin and Glucagon in Postprandial Glycemic Excursions in Pediatric Type 1 Diabetes. Rubina Heptulla MD, Luisa M. Rodriguez MD and Morey W. Haymond.

Advertisements

Philip J. Barter, et al. Circulation 2011;124:

GLP-1 Effectiveness, Mechanisms of Action and Potential Part 2.

Plasma insulin concentrations (A) and insulin secretion rates (B) in response to molar increments of plasma glucose concentration during the graded glucose.

Sofie Hædersdal, MD, Asger Lund, MD, PhD, Filip K

Glucose homeostasis: roles of insulin and glucagon. 1A.

Safia Costes, Peter C. Butler Cell Metabolism

Pramlintide Synthetic analog of the β-cell hormone amylin

Glucose homeostasis: roles of insulin, glucagon, amylin, and GLP-1.

Postprandial glucose flux in nondiabetic controls.

Update on cystic fibrosis-related diabetes

Topic – Homeostasis Stephen Taylor.

Comparison of triglycerides AUC 480’ between IGT+reduced FPIS group, IGT+preserved FPIS group, and IGT+reduced FPIS+reduced FPIS and FPIS restitution with.

Central nervous system BDNF infusion fails to increase tissue glucose uptake in uncontrolled insulin-deficient diabetes. Central nervous system BDNF infusion.

Cyp8b1−/− mice have improved islet insulin secretion and increased islet insulin content but unchanged β-cell mass. Cyp8b1−/− mice have improved islet.

Hyperinsulinemic-euglycemic clamp–derived insulin sensitivity (glucose disposal), model-derived insulin secretion parameters (sensitivity first-phase insulin.

The development of plasma (p-)C-peptide responses to an intravenous glucose (0.5 g glucose/kg body wt) and glucagon (1 mg) infusion test up to 5–7 years.

Correlation between muscle Hsp-72 mRNA expression and rates of glucose and lipid turnover, as determined in protocol 2 (n = 36). Correlation between muscle.

Involvement of IRS-1 in L-783,281–stimulated increases in [Ca2+]i and exocytosis. Involvement of IRS-1 in L-783,281–stimulated increases in [Ca2+]i and.

Changes (mean +SEM) in glucose, insulin, glucagon-like peptide (GLP)-1 and ghrelin from the baseline values after administration of placebo (broken lines.

Plasma glucose (A) and glucose specific activity (B) during euglycemic clamp experiments. Plasma glucose (A) and glucose specific activity (B) during euglycemic.

Model for the regulation of insulin secretion in the β-cell stimulated by glucose and amino acids. Model for the regulation of insulin secretion in the.

Omental FFA production, calculated from the integrated lipolysis over the last 30 min of each insulin infusion period. Omental FFA production, calculated.

Glucose infusion rate required to maintain the hyperglycemic clamp during the experimental period in sedentary and exercised dogs receiving basal or elevated.

α-Cells mainly express SSTR2 and SSTR3

Models of the mechanisms by which sulfonylureas and glucose control glucagon release. Models of the mechanisms by which sulfonylureas and glucose control.

In the absence of SST, 20 or 30 mmol/L glucose stimulates glucagon release. In the absence of SST, 20 or 30 mmol/L glucose stimulates glucagon release.

Defective response to insulin secretagogues may arise from A) decreased concentrations of a given secretagogue, B) loss of β-cell responsiveness to that.

Glycemia and glucose tolerance of RIP-N mice.

Insulin secretion/insulin resistance (disposition) index (ΔINS/ΔGLU ÷ IR) in subjects with normal glucose tolerance (NGT), impaired glucose tolerance (IGT),

Left columns: Plasma glucose and serum insulin concentrations, circulating TF-PCA, and FVIIa activity before and during 24 h of selective hyperglycemia.

A single dose of liraglutide (Lira) (7. 5 μg/kg or 0

Grg3 works with Pdx1 to repress α-cell genes and induce glucose-stimulated insulin secretion. Grg3 works with Pdx1 to repress α-cell genes and induce glucose-stimulated.

Zn2+ and NAD(P)H content in Mafa∆panc and Mafa∆panc;Mafb+/− β-cells.

Comparison of women carrying a male fetus and those carrying a female fetus, with respect to mean adjusted blood glucose levels during the OGTT (A), mean.

The underlying physiological basis of the HOMA model.

Grg3 is expressed in most β-cells but less frequently in α-cells.

SGLT 2 transporter mRNA (left) and protein (middle) and glucose transport (α-methyl-d-glucopyranoside) (right) are increased in cultured renal proximal.

Somatostatin released by δ-cells exerts a tonic inhibition on glucagon and insulin secretion but is not required for the glucagonostatic effect of glucose.

ATL-801 treatment increases insulin sensitivity in KKAY mice.

Glucose control performance (by CGM) characterized by median and interquartile range cumulative % time in glucose range (A), overall glucose (B), and insulin.

Total plasma BCAA (A) and C3 and C5 acylcarnitine (AC) (B) concentrations in the basal state and during insulin infusion in obese subjects before and after.

ChREBPα increases β-cell mitochondrial activity and ATP production in human islets. ChREBPα increases β-cell mitochondrial activity and ATP production.

Plasma concentrations of glucose, insulin, C-peptide and glucagon observed in subjects with NFG/NGT, NFG/IGT, IFG/NGT, and IFG/IGT-D following ingestion.

The lack of effect of denatonium to stimulate insulin release in the absence of extracellular Ca2+ or in the presence of 10 μmol/l nitrendipine. The lack.

Mean (±SE) plasma glucose concentrations before, during, and after infusions of octreotide (with growth hormone) with saline (•), with insulin replacement.

Food intake in response to central infusion of glucose (squares) or insulin (triangles) and in response to successive central infusion of insulin, insulin.

Glucose-stimulated insulin secretion, plasma glucagon levels, and pancreatic hormone contents. Glucose-stimulated insulin secretion, plasma glucagon levels,

Plasma glucose, GIR, rates of EGP and glucose utilization, and plasma concentrations of free fatty acids (FFAs) and β-hydroxy-butyrate after a subcutaneous.

PKA inhibitors do not markedly affect the potentiation of glucose-induced insulin release by GLP-1. PKA inhibitors do not markedly affect the potentiation.

Loss of Phb2 in β-cells induces development of diabetes over a 3-week period in β-Phb2−/− mice. Loss of Phb2 in β-cells induces development of diabetes.

Comparison of the percentages of ducts in the pancreas containing cells showing positive staining for the different markers between control patients and.

Chronic rapamycin treatment impairs β-cell mass and insulin clearance in rats. Chronic rapamycin treatment impairs β-cell mass and insulin clearance in.

(A) Oral glucose tolerance test (OGTT) glucose and (C) natural logarithm of insulin responses over time with SEM bars comparing the first tertile to the.

Effect of GSK-3 inhibitors on basal and insulin-stimulated glucose uptake in human muscle cells. Effect of GSK-3 inhibitors on basal and insulin-stimulated.

Metabolic parameters in the three groups of patients during l-arginine infusion. Metabolic parameters in the three groups of patients during l-arginine.

Effects of vinegar (□) and placebo (⧫) on plasma glucose (A–C) and insulin (D–F) responses after a standard meal in control subjects, insulin-resistant.

RBP4 and glucose metabolism.

(A) Mean glucose concentrations (standard error) over a 3-hour period in 21 placebo- and 15 pramlintide-treated patients with type 1 diabetes treated for.

The hyperbolic relationship between fasting insulin and Si (A) and AIRg and Si (B) for NFG (FPG

Plasma glucose (A), serum insulin (B), serum C peptide (C) and plasma GLP-1 level (D) during the 2-hour OGTT among subjects with normal glucose tolerance.

Postprandial glucose, insulin and glucagon-like peptide-1 (GLP-1) levels following carbohydrate-first (CF), carbohydrate-last (CL) and sandwich (S) meal.

Pathophysiology and drug targets.

Spearman rank order correlation between suppression of hepatic glucose production with low insulin infusion and 30-min change in glucose response in women.

Plasma concentration of metabolite M1 (left panel), glucose infusion rate (GIR) to maintain euglycemia (middle panel), and blood glucose concentration.

An insulin simplification regimen: from multiple injections to once-daily long-acting (basal) insulin plus noninsulin agents. *Basal insulins: glargine.

The Stomach in Diabetes: From Villain to Ally

(A) Twenty-four-hour plasma profiles of insulin and amylin in healthy subjects. (A) Twenty-four-hour plasma profiles of insulin and amylin in healthy subjects.

Insulin secretion (hyperglycemic clamp) (A), insulin sensitivity (hyperinsulinemic-euglycemic clamp) (B), and glucose disposition index (GDI) (C) in adolescents.

Presentation transcript:

Insulin and glucagon secretion: nondiabetic and diabetic subjects. Insulin and glucagon secretion: nondiabetic and diabetic subjects. In nondiabetic subjects (left panel), glucose-stimulated insulin and amylin release from the β-cells results in suppression of postprandial glucagon secretion. In a subject with type 1 diabetes, infused insulin does not suppress α-cell production of glucagon. Adapted from Ref. 38. Stephen L. Aronoff et al. Diabetes Spectr 2004;17:183-190 ©2004 by American Diabetes Association